The Use of Therapeutic Apheresis in Dermatology

1.    BLÁHA, V., BLÁHA, M., PIŤHA, J. et al. Iniciativa k ustavení aferetických center: indikace a provádění lipoproteinové aferézy v České republice. AtheroRev, 2019, 4(1), p. 19–27.

2.    DIETZE, J., HOHENSTEIN, B., TSELMIN, S. et al. Successful and well-tolerated bi-weekly immunoadsorption regimen in pemphigus vulgaris. Atheroscler Suppl, 2017, 30, p. 271–277.

3.    EMING, R., RECH, J., BARTH, S. et al. Prolonged clinical remission of patients with severe pemphigus upon rapid removal of desmoglein-reactive autoantibodies by immunoadsorption. Dermatology, 2006, 212, p. 177–187.

4.    FUJISAWA, T., MORIYA, CH., SHIBUYA, Y. et al. Combination Therapy of Infliximab and Granulocyte/Monocyte Adsorption Apheresis for Refractory Pustular Psoriasis with Psoriatic Arthritis. Acta Derm Venereol, 2013, 93, p. 364–365.

5.    GÜNTHER, C., LASKE, J., FRIND, A. et al. Successful therapy of pemphigus vulgaris with immunoadsorption using the TheraSorb adsorber. J Dtsch Dermatol Ges, 2008, 6, p. 661–663.

6.    HERRERO-GONZÁLEZ, J. E., SITARU, C., KLINKER, E. et al. Successful adjuvant treatment of severe bullous pemphigoid by tryptophan immunoadsorption. Clin Exp Dermatol, 2005, 30, p. 519–522.

7.    HOFRICHTER, M., DWORSCHAK, J., EMTENANI, S. et al. Immunoadsorption of Desmoglein-3-Specific IgG Abolishes the Blister-Inducing Capacity of Pemphigus Vulgaris IgG in Neonatal Mice. Front. Immunol, 2018, https://doi.org/10.3389/fimmu.2018.01935.

8.    HOLTSCHE, M. M., ZILLIKENS, D., SCHMIDT, E. Mucous membrane pemphigoid. Hautarzt, 2018, 69(1), p. 67–83.

9.    HÜBNER, F., KASPERKIEWICZ, M., KNUTH-REHR, D. et al. Adjuvant treatment of severe/refractory bullous pemphigoid with protein A immunoadsorption. J Dtsch Dermatol Ges, 2018,16, p. 1109–1118.

10. INO, N., KAMATA, N., MATSUURA, C. et al. Immunoadsorption for the treatment of bullous pemphigoid. Ther Apher, 1997,1(4), p. 372–376.

11. JOLY, P., BARICAULT, S., SPARSA, A. et al. Incidence and mortality of bullous pemphigoid in France. J Invest Dermatol., 2012, 132(8), p. 1998–2004.

12. KASPERKIEWICZ, M., HOPPE, U., ZILLIKENS, D. et al. Relapse-associated autoantibodies to BP180 in a patient with anti-p200 pemphigoid. Clin Exp Dermatol, 2010, 35(6), p. 614–617.

13. KASPERKIEWICZ, M., MEIER, M., ZILLIKENS, D. et al. Linear IgA disease: successful application of immunoadsorption and review of the literature. Dermatology, 2010, 220(3), p.259–263.

14. KASPERKIEWICZ, M., SCHULZE, F., MEIER, M. et al. Treatment of bullous pemphigoid with adjuvant immunoadsorption: a case series. J Am Acad Dermatol, 2014, 71(5), p. 1018–1020.

15.   Kasperkiewicz, M., Mook, S. C., Knuth-Rehr, D. et al. IgE-Selective Immunoadsorption for Severe Atopic Dermatitis. Front Med (Lausanne), 2018, 5, p. 27.

16. Kolesnik, M., Becker, E., Reinhold, D. et al. Treatment of severe autoimmune blistering skin diseases with combination of protein A immunoadsorption and rituximab: a protocol without initial high dose or pulse steroid medication. J Eur Acad Dermatol Venereol, 2014, 28(6), p. 771–780.

17. LÜFTL, M., STAUBER, A., MAINKA, A. et al. Successful removal of pathogenic autoantibodies in pemphigus by immunoadsorption with a tryptophan-linked polyvinylalcohol adsorber. Br J Dermatol, 2003, 149(3), p. 598–605.

18. MARKER, M., DERFLER, K., MONSHI, B. et al. Successful immunoapheresis of bullous autoimmune diseases: pemphigus vulgaris and pemphigoid gestationis. JDDG, 2011, 9, p.27–31.

19. MEYERSBURG, D., SCHMIDT, E., KASPERKIEWICZ, M. et al. Immunoadsorption in dermatology. Ther Apher Dial, 2012,16, p. 311–320.

20. MURRELL, D. F., PEŃA, S., JOLY, P. et al. Diagnosis and Management of Pemphigus: recommendations by an International Panel of Experts. J Am Acad Dermatol, 2018, pii: S0190-9622(18)30207-X. doi: 10.1016/j.jaad.2018.02.021, update JAAD 82/3 2020 p. 575–585.

21. MÜLLER, P. A., BRÖCKER, E. B., KLINKER, E. et al. Adjuvant treatment of recalcitrant bullous pemphigoid with immunoadsorption. Dermatology, 2012, 224(3), p. 224–227.

22. NIEDERMEIER, A., EMING, R., PFÜTZE, M. et al. Clinical response of severe mechanobullous epidermolysis bullosa acquisita to combined treatment with immunoadsorption and rituximab (anti-CD20 monoclonal antibodies). Arch Dermatol, 2007, 143(2), p. 192–198.

23. PADMANABHAN, A., CONNELLY‐SMITH, L., AQUI, N. et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eigth Special Issue. J Clin Apher., 2019, 34, p. 171–354.

24. RECKE, A., SHIMANOVICH, I., STEVEN, P. et al. Treatment-refractory anti-laminin 332 mucous membrane pemphigoid. Remission following adjuvant immunoadsorption and rituximab. Hautarzt, 2011, 62(11), p. 852–858.

25. SHIMANOVICH, I., HERZOG, S., SCHMIDT, E. et al. Improved protocol for treatment of pemphigus vulgaris with protein A immunoadsorption. Clin Exp Dermatol, 2006, 31(6), p. 768–774.

26. SHIMANOVICH, I., NITSCHKE, M., ROSE, C. et al. Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins. Br J Dermatol, 2008, 158(2), p. 382–388.

27. SHIMOYAMA, T., YAMAMOTO, T., UMEGAE, S. et al. Faecal calprotectin level for assessing endoscopic activity and predicting future clinical course in patients with moderately active ulcerative colitis undergoing granulomonocytapheresis: a prospective cohort study. BMC Gastroenterol, 2018, 18, p. 120.

28. SCHMIDT, E., KLINKER, E., OPITZ, A. et al. Protein A immunoadsorption: a novel and effective adjuvant treatment of severe pemphigus. Br J Dermatol, 2003, 148(6), p. 1222–1229.

29. SCHMIDT, E., ZILLIKENS, D. Immunoadsorption in dermatology. Arch Dermatol Res, 2010, 302(4), p. 241–253.

30. TSELMIN, S., JULIUS, U., BORNSTEIN, S. R. et al. Low rate of infectious complications following immunoadsorption therapy without regular substitution of intravenous immunoglobulins. Atheroscler Suppl, 2017, 30, p. 278–282.

31. Westermann, L., Hügel, R., Meier, M. et al. Glucocorticosteroid-resistant pemphigoid gestationis: successful treatment with adjuvant immunoadsorption. J Dermatol, 2012, 39(2), p.168–171.

32. WÖHRL, S., GEUSAU, A., KARLHOFER, F. et al. Pemphigoid gestationis: treatment with immunoapheresis. J Dtsch Dermatol Ges, 2003,1(2), p. 126–130.

33. ZILLIKENS, D., DERFLER, K., EMING, R. et al. Recommendations for the use of immunoapheresis in the treatment of autoimmune bullous diseases. J Dtsch Dermatol Ges, 2007, 5(10), p. 881–887.

34. ZIC, J. A. Extracorporeal Photopheresis in the Treatment of Mycosis Fungoides and Sézary Syndrome. Dermatologic Clinics, 2015, 33, p. 765–776.

35. ZINK, A., GENSBAUR, A., ZIRBS, M. et al. Targeting IgE in severe atopic dermatitis with a combination of immunoadsorption and omalizumab. Acta Derm Venereol, 2016, 96, p. 72–76.